<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878719</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-162-115</org_study_id>
    <secondary_id>C4221011</secondary_id>
    <nct_id>NCT03878719</nct_id>
  </id_info>
  <brief_title>Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma</brief_title>
  <official_title>A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pierre Fabre Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and&#xD;
      efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF&#xD;
      V600-mutant advanced/metastatic melanoma. The study consists of a Safety Run-in Phase to&#xD;
      determine the RDE (recommended dose in expansion), followed by an Expansion Phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">September 5, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameter (time to reach the maximum observed plasma concentration Cmax [Tmax]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (time of last PK sample [Tlast]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (area under the plasma concentration-time curve from time zero to Tlast [AUClast]) for binimetinib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for binimetinib's active metabolite (AR00426032)</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for AR00426032</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for encorafenib</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tmax) for encorafenib's metabolite (LHY746)</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Cmax) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Tlast) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (AUClast) for LHY746</measure>
    <time_frame>Day 1 and Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (trough concentration [Ctrough]) for binimetinib</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for AR00426032</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for encorafenib</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 15 of Cycle 1, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 1 of Cycle 2, 28 day cycles</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter (Ctrough) for LHY746</measure>
    <time_frame>at time zero Day 1 of Cycle 3, 28 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs)</measure>
    <time_frame>From informed consent up to 30 days following last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>Duration of treatment for safety run-in phase, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability score for the pediatric formulations as assessed by an age-appropriate questionnaire for binimetinib</measure>
    <time_frame>Through Cycle 3 Day 1 in patients receiving the pediatric formulations in the Expansion Phase, 28 day cycles</time_frame>
    <description>Five-point Hedonic scale from 1 to 5, 5=really good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palatability score for the pediatric formulations as assessed by an age-appropriate questionnaire for encorafenib</measure>
    <time_frame>Through Cycle 3 Day 1 in patients receiving the pediatric formulations in the Expansion Phase, 28 day cycles</time_frame>
    <description>Five-point Hedonic scale from 1 to 5, 5=really good</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) assessed by the investigator, based on Response Criteria Evaluation in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year survival rate</measure>
    <time_frame>From first dose up to 1 year after treatment initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline bone age and the difference in bone age and chronological age</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in bone densitometry based on dual energy X-ray absorptiometry (DEXA) scan.</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in calcium-phosphorus product (Ca × P)</measure>
    <time_frame>Duration of treatment, approximately 6 months, 28 day cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>binimetinib taken twice daily (BID) and&#xD;
encorafenib taken once daily (QD)&#xD;
Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>binimetinib taken twice daily (BID) and&#xD;
encorafenib taken once daily (QD)&#xD;
Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>encorafenib</intervention_name>
    <description>taken orally</description>
    <arm_group_label>Expansion Phase</arm_group_label>
    <arm_group_label>Safety Run-in Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following criteria to be eligible for enrollment in the&#xD;
        study.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of locally advanced, unresectable or metastatic&#xD;
             cutaneous melanoma or unknown primary melanoma American Joint Committee on Cancer&#xD;
             Stage IIIB, IIIC, or IV.&#xD;
&#xD;
          -  Presence of BRAF V600E or V600K mutation in tumor tissue as determined by a local or&#xD;
             central laboratory&#xD;
&#xD;
          -  Adequate cardiac function:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≥ 50% as determined by ECHO or&#xD;
                  multi-gated acquisition (MUGA) scan and above the institutional lower limit of&#xD;
                  normal (LLN);&#xD;
&#xD;
               -  Triplicate average baseline QTcF value ≤ 450 ms.&#xD;
&#xD;
          -  Adequate bone marrow, organ function, and laboratory parameters:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL with or without transfusions;&#xD;
&#xD;
               -  Platelets ≥ 75 × 10⁹/L without transfusions;&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 ×&#xD;
                  upper limit of normal (ULN); in patients with liver metastases ≤ 5 × ULN;&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
               -  Creatinine ≤ 1.5 × institutional ULN for age, or calculated creatinine clearance&#xD;
                  ≥ 70 mL/min/1.73 m² (following Schwartz formula).&#xD;
&#xD;
          -  Adequate performance status at Screening:&#xD;
&#xD;
               -  Patients &lt; 16 years old: Lansky Performance Scale score ≥ 80&#xD;
&#xD;
               -  Patients 16 to 17 years old: Karnofsky Performance Scale score ≥ 80&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following criteria are not eligible for enrollment in the&#xD;
        study.&#xD;
&#xD;
          -  Uveal or mucosal melanoma.&#xD;
&#xD;
          -  Brain metastases that are uncontrolled or symptomatic, require steroids, are&#xD;
             potentially life-threatening or have required radiation within 28 days prior to&#xD;
             starting study drug.&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO&#xD;
&#xD;
          -  Prior therapy with a BRAF inhibitor (e.g., dabrafenib, vemurafenib) and/or a MEK&#xD;
             inhibitor (e.g., trametinib, cobimetinib).&#xD;
&#xD;
          -  Impaired cardiovascular function or clinically significant cardiovascular disease,&#xD;
             including any of the following:&#xD;
&#xD;
               -  History of acute coronary syndromes (including myocardial infarction, unstable&#xD;
                  angina, coronary artery bypass grafting, coronary angioplasty or stenting) &lt; 6&#xD;
                  months prior to screening,&#xD;
&#xD;
               -  Symptomatic chronic heart failure, history or current evidence of clinically&#xD;
                  significant cardiac arrhythmia and/or conduction abnormality &lt; 6 months prior to&#xD;
                  screening except atrial fibrillation and paroxysmal supraventricular tachycardia.&#xD;
&#xD;
          -  Concurrent neuromuscular disorder associated with elevated creatine kinase (CK)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension despite medical treatment&#xD;
&#xD;
          -  Presence of BRAFʷͭ or indeterminate melanoma in tumor tissue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Childrens Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash University - Monash Health - Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorium profesora Arenbergera</name>
      <address>
        <city>Praha 1</city>
        <zip>11000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lekarna U sv. Ignace</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>Lombardy</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AOU Citta della Salute e della Scienza- Presidio Ospedaliero Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <state>Turin</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo studio e la Cura dei tumori Fondazione Senatore Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Capital and Coast District Health Board</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Czechia</country>
    <country>Italy</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=ARRAY-162-115</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent</keyword>
  <keyword>BRAF V600K</keyword>
  <keyword>BRAF V600E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

